Is gosatuzumab (Todavi) covered by medical insurance? Can patients be reimbursed through medical insurance?

Gosatuzumab (Trodelvy, trade name: Trodelvy) is a targeted drug used to treat triple-negative breast cancer. Its mechanism of action mainly targets and kills tumor cells through antibody drug conjugates (ADC). Trodelvy was approved by the US FDA in 2020 for the treatment of patients with locally advanced or metastatic triple-negative breast cancer (TNBC), and has been approved in multiple countries and regions, becoming an innovative drug in this field.

As for whether it has been included in medical insurance, gosatuzumab (Trodelvy) is currently not fully covered by medical insurance in China. Although the drug has entered the medical insurance catalog of some countries in 2022, medical insurance reimbursement in China is still relatively lagging behind. At present, gosatuzumab (Trodelvy) has not been officially included in China's national medical insurance directory, so patients may not be able to enjoy medical insurance reimbursement when receiving treatment. Patients need to bear the cost of the drugs themselves, which are usually relatively expensive and may bring a greater burden to patients with tight financial conditions.

However, as cancer treatment drugs gradually become part of China's medical insurance reform, the possibility of gosatuzumab (Trodelvy) entering medical insurance still exists. In recent years, the National Medical Insurance Administration has continuously increased its coverage of cancer drugs, and has especially actively promoted the introduction of some innovative drugs. In the future, with the accumulation of more data and the demonstration of clinical effects, gosatuzumab (Trodelvy) is expected to be included in the medical insurance catalog, allowing more patients to be reimbursed by medical insurance, thereby alleviating financial pressure.

In summary, gosatuzumab (Trodelvy) has not yet been officially included in China’s medical insurance catalog, so patients cannot reimburse the cost through medical insurance. It is hoped that with the continuous optimization of medical insurance policies, financial support can be provided to more patients who need this drug treatment in the future.

Reference materials:https://www.trodelvy.com/